daraxonrasib trials for Non-small Cell Lung Cancer (NSCLC)

All daraxonrasib trials · All Non-small Cell Lung Cancer (NSCLC) trials

Phase breakdown

Recruiting trials studying daraxonrasib for Non-small Cell Lung Cancer (NSCLC)

• Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
  NCT06128551 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 55 locations
• Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
  NCT07397338 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 9 locations
• Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
  NCT07349537 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 9 locations

Common questions

How many trials study daraxonrasib for Non-small Cell Lung Cancer (NSCLC)?

3 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.